PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
about
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesRecent Updates on the Management of Medullary Thyroid CarcinomamiR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cellsPTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinomaA systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceCombinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer CellsEDAG-1 promotes proliferation and invasion of human thyroid cancer cells by activating MAPK/Erk and AKT signal pathways.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600ESelective use of vandetanib in the treatment of thyroid cancer.PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Extract of Spatholobus suberctus Dunn ameliorates ischemia-induced injury by targeting miR-494.Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathwaysMicroRNA-210 Protects PC-12 Cells Against Hypoxia-Induced Injury by Targeting BNIP3Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.BCL6B suppresses proliferation and migration of colorectal carcinoma cells through inhibition of the PI3K/AKT signaling pathway.Cancer Nanotechnology: Opportunities for Prevention, Diagnosis, and Therapy.lncRNA CCAT1 promotes cell proliferation, migration, and invasion by down-regulation of miR-143 in FTC-133 thyroid carcinoma cell line.
P2860
Q26750748-DB29E418-F21D-4047-A96E-F04AC2498587Q28066911-CC51F7CE-BB14-4741-8793-28554656516FQ33709554-CB28A89B-B0D8-469D-95B0-B62A8E8E0BFEQ36057504-7C823694-605A-4890-9168-157BA34D2B79Q36086862-5E9BF453-0F80-460D-81D5-8177217403BBQ36215991-EB57A830-1DA2-4AB3-A16B-9AAABA81D399Q36544718-5C740E07-DDB8-4608-861F-BF9EC2E2AB51Q36909931-0CC6F59F-9F05-46AF-84C3-F5EEE15D6A6DQ37013328-9982D1D7-BE00-45F8-B97F-E16F0EF034BDQ37091117-BC16FFD1-520C-4B1B-8F6A-6687491D0819Q37392688-DBF932B2-E113-4274-94E3-00AC8175AAB1Q37746163-4C9FDE37-7B37-424B-B069-580190D1099CQ38546474-4C5D5744-D7C3-40EF-9351-7C99F2C912D6Q38644584-25BC0BA9-2050-4FCD-A761-E6BCE2F534F6Q38743093-CDB15688-0A66-4BAC-88B9-D2A140427BA4Q38789650-9B734EA1-03E4-4788-B635-2223BE4FCF0DQ39201601-2D6F5E34-1202-44EC-BBEF-DF486DBC425DQ41194522-F352F38E-4F39-45D4-B98E-DBF448FFBB9BQ41570863-D0CBAFA6-F09A-470E-AC42-009A5922F4D3Q42242030-D11CD689-B3C4-484E-ABBB-5D861E8ED84AQ42364538-1F3E13FB-40E2-40C2-A08A-E5E5CA88DAE3Q47123875-2BB24F55-0800-443B-819D-ABD3CE4BC951Q47395532-61050807-9449-4BEC-86E0-FA6A6AC80F24Q49379642-96C40F70-A4C9-4E33-AD67-A0EA0C7D4F79Q53533429-42151964-FAD7-4DE1-AD79-92640131E481Q55470742-06D35D18-AB13-4938-A53C-0520A16FEC0B
P2860
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PI3K/Akt/mTOR signaling in med ...... lar target for cancer therapy.
@en
type
label
PI3K/Akt/mTOR signaling in med ...... lar target for cancer therapy.
@en
prefLabel
PI3K/Akt/mTOR signaling in med ...... lar target for cancer therapy.
@en
P2093
P2860
P1433
P1476
PI3K/Akt/mTOR signaling in med ...... lar target for cancer therapy.
@en
P2093
Alessandra Dicitore
Germano Gaudenzi
Giovanni Vitale
Gloria Irene Manfredi
P2860
P2888
P304
P356
10.1007/S12020-014-0380-1
P577
2014-08-13T00:00:00Z